AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9460820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 8590535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 77
Study 8590535 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 77
Study 8590535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study 8590535 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ST shift > or = 60 min
Number of subjects: 77
Study 2171852 — intervention group
Group type: COMPARATOR
Intervention: Oral amiloride 20 mg
Number of subjects: 43
Study 2171852 — intervention group
Group type: COMPARATOR
Intervention: Inhaled amiloride 10 ml of 10(‐2) mol/l
Number of subjects: 43
Study 9581 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (C) 10 mg t.i.d. for 7 days, 20 mg t.i.d. for 7 days + Alcohol (A) 0.5 g/kg
Number of subjects: 37
Study 9581 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine (T) 10 mg t.i.d. for 7 days, 20 mg t.i.d. for 7 days
Number of subjects: 37
Study 9581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (S) 50 mg t.i.d. + Alcohol (A) 0.5 g/kg
Number of subjects: 37
Study 9581 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (B) 6 mg t.i.d. + Alcohol (A) 0.5 g/kg
Number of subjects: 37
Study 9581 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (T) + Alcohol (A) 0.5 g/kg
Number of subjects: 37
Study 9581 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (C) + Alcohol (A) 0.5 g/kg
Number of subjects: 37
Study 9581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (S) + Alcohol (A) 0.5 g/kg
Number of subjects: 37
Study 9581 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (B) + Alcohol (A) 0.5 g/kg
Number of subjects: 37
Study 9581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 37
Study 30508769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 40
Study 28703504 — intervention group
Group type: EXPERIMENTAL
Intervention: MEND/CATCH6-12 (121.5 contact hours)
Number of subjects: 549
Study 28703504 — intervention group
Group type: COMPARATOR
Intervention: Next Steps (8 contact hours)
Number of subjects: 549
Study 28703504 — intervention group
Group type: EXPERIMENTAL
Intervention: MEND2-5 (27 contact hours)
Number of subjects: 549
Study 28703504 — intervention group
Group type: COMPARATOR
Intervention: Both programs
Number of subjects: 549
Study 28703504 — intervention group
Group type: COMPARATOR
Intervention: MEND/CATCH6-12 and Next Steps
Number of subjects: 549
Study 26316279 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning conversation
Number of subjects: 640
Study 26316279 — intervention group
Group type: COMPARATOR
Intervention: Sandwich technique
Number of subjects: 640
Study 23944208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation assessment using a scale in intubated and ventilated patients
Number of subjects: 569
Study 23944208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment
Number of subjects: 569
Study 23944208 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pain
Number of subjects: 569
Study 23944208 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 569
Study 23944208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation levels assessment
Number of subjects: 569
Study 23944208 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium assessment
Number of subjects: 569
Study 23944208 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of restraints
Number of subjects: 569
Study 20675107 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat consumption (quintiles of intake)
Number of subjects: 21120
Study 18520336 — intervention group
Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus GG, Bifidobacterium lactis, Streptococcus thermophilus, Lactobacillus reuteri)
Number of subjects: 0
Study 18520336 — intervention group
Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus GG, Bifidobacterium spp., Streptococcus spp., Saccharomyces boulardii)
Number of subjects: 0
Study 18520336 — intervention group
Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus GG, S. boulardii, L. reuteri)
Number of subjects: 0
Study 18520336 — intervention group
Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus GG, S. boulardii)
Number of subjects: 0
Study 13678108 — intervention group
Group type: EXPERIMENTAL
Intervention: DentiPatch (lidocaine patch)
Number of subjects: 30
Study 13678108 — intervention group
Group type: COMPARATOR
Intervention: Benzocaine gel
Number of subjects: 30
Study 10618302 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) frequency
Number of subjects: 1080
Study 10618302 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables
Number of subjects: 1080
Study 10618302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular arrhythmias
Number of subjects: 1080
Study 10618302 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic NSVT on ambulatory ECG
Number of subjects: 1080
Study 8885036 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash injury patients
Number of subjects: 30
Study 1597844 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g of an oil preparation rich in C18:3n-6, C20:5n-3 and C22:6n-3
Number of subjects: 18
Study 1597844 — intervention group
Group type: COMPARATOR
Intervention: 4g sunflower seed oil
Number of subjects: 18
Study 6204153 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics as sole therapy
Number of subjects: 0
Study 6204153 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics combined with alpha-methyldopa or propranolol
Number of subjects: 0
Study 30264178 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 6
Study 29072209 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 24
Study 29072209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 24
Study 29072209 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 24
Study 26216382 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (fixed dose 120 mg)
Number of subjects: 346
Study 26216382 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (low/standard/high doses: 200/300/600 mg)
Number of subjects: 346
Study 26216382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both febuxostat and allopurinol
Number of subjects: 346
Study 24352085 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg allopurinol intravenously to the mother immediately prior to delivery
Number of subjects: 58
Study 24352085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 22929602 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 20
Study 22929602 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture with percutaneous electrical nerve stimulation (PENS)
Number of subjects: 20
Study 20712602 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 314
Study 20712602 — intervention group
Group type: COMPARATOR
Intervention: Thermal balloon endometrial ablation (TBALL)
Number of subjects: 314
Study 17554155 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback plus information (FB+I)
Number of subjects: 177
Study 17554155 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback (FB)
Number of subjects: 177
Study 17554155 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 177
Study 15661234 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m², Carboplatin AUC 5, Gemcitabine 800 mg/m² on day 1 and Gemcitabine 800 mg/m² on day 8, every 3 weeks
Number of subjects: 55
Study 12028981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (general practitioner letter inviting consultation and management guidelines)
Number of subjects: 1932
Study 12028981 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual general practitioner care)
Number of subjects: 1932
Study 12028981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1932
Study 10468948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 15 mg/day
Number of subjects: 9
Study 10468948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 20 mg/day
Number of subjects: 9
Study 10468948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 30 mg/day
Number of subjects: 9
Study 10468948 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessments (BBS, Bf-S, BL)
Number of subjects: 9
Study 7533447 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 0
Study 7533447 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study 7533447 — intervention group
Group type: EXPERIMENTAL
Intervention: TUMT
Number of subjects: 0
Study 1694831 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion (2-4 ng/kg/min for 12 hours daily on 5 consecutive days)
Number of subjects: 13
Study 1694831 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 13
Study 1694831 — intervention group
Group type: COMPARATOR
Intervention: Dextran infusion
Number of subjects: 13
Study 293032 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptic (standard composite material)
Number of subjects: 0
Study 293032 — intervention group
Group type: EXPERIMENTAL
Intervention: Estic microfill (newly developed composite material)
Number of subjects: 0
Study 293032 — intervention group
Group type: COMPARATOR
Intervention: Amalgam (Dispersalloy)
Number of subjects: 0
Study 31774950 — intervention group
Group type: EXPERIMENTAL
Intervention: MAb114
Number of subjects: 681
Study 31774950 — intervention group
Group type: COMPARATOR
Intervention: ZMap
Number of subjects: 681
Study 31774950 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN-EB3
Number of subjects: 681
Study 31774950 — intervention group
Group type: COMPARATOR
Intervention: ZMap subgroup
Number of subjects: 681
Study 27876559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant hand for puncture
Number of subjects: 20
Study 27876559 — intervention group
Group type: COMPARATOR
Intervention: Dominant hand for puncture
Number of subjects: 20
Study 25867847 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplements
Number of subjects: 12
Study 25867847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23046314 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based humanistic counseling (SBHC) for 12 weeks
Number of subjects: 33
Study 23046314 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 33
Study 21098802 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-monthly screening
Number of subjects: 22634
Study 21098802 — intervention group
Group type: COMPARATOR
Intervention: 12-monthly screening
Number of subjects: 22634
Study 19251004 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent hood
Number of subjects: 592
Study 19251004 — intervention group
Group type: COMPARATOR
Intervention: No hood
Number of subjects: 592
Study 18317624 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 40 microg/kg
Number of subjects: 160
Study 18317624 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 40 microg/kg
Number of subjects: 160
Study 18317624 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.5 microg/kg
Number of subjects: 160
Study 18317624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of midazolam and clonidine (40 microg/kg and 0.5 microg/kg respectively)
Number of subjects: 160
Study 18317624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diazepam and clonidine (40 microg/kg and 0.5 microg/kg respectively)
Number of subjects: 160
Study 15774240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with vinorelbine and estramustine phosphate plus ellagic acid (group B)
Number of subjects: 0
Study 15774240 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with vinorelbine and estramustine phosphate (group A)
Number of subjects: 0
Study 12399790 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based health promotion screening
Number of subjects: 248
Study 12399790 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 248
Study 9865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (prophylactic dose)
Number of subjects: 99
Study 9865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 99
Study 9865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 99
Study 9865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim and sulfamethoxazole
Number of subjects: 99
Study 9865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid
Number of subjects: 99
Study 9865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 99
Study 9865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 99
Study 8556030 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-culture of embryos with Vero cell monolayer
Number of subjects: 75
Study 8556030 — intervention group
Group type: COMPARATOR
Intervention: Conventional culture without Vero cell monolayer
Number of subjects: 75
Study 2294131 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening GH injections (2000 h)
Number of subjects: 8
Study 2294131 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning GH injections (0800 h)
Number of subjects: 8
Study 2294131 — intervention group
Group type: COMPARATOR
Intervention: No GH administration
Number of subjects: 8
Study 368086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (600 mg per day)
Number of subjects: 35
Study 368086 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3600 mg per day)
Number of subjects: 35
Study 368086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 35
Study 368086 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 35
Study 31913829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaver training
Number of subjects: 78
Study 31913829 — intervention group
Group type: COMPARATOR
Intervention: Manikin training
Number of subjects: 78
Study 30052592 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-Assisted Treatment (MAT)
Number of subjects: 10
Study 30052592 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant relationships with healthcare providers
Number of subjects: 10
Study 27966508 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 20
Study 27966508 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft (ABG)
Number of subjects: 20
Study 23180287 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT + action-planning
Number of subjects: 60
Study 23180287 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT + action-and-coping-planning
Number of subjects: 60
Study 23180287 — intervention group
Group type: COMPARATOR
Intervention: PMT-only
Number of subjects: 60
Study 22133627 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition training
Number of subjects: 24
Study 22133627 — intervention group
Group type: COMPARATOR
Intervention: Imitation training
Number of subjects: 24
Study 22133627 — intervention group
Group type: COMPARATOR
Intervention: General inhibition training
Number of subjects: 24
Study 22133627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study 20457817 — intervention group
Group type: COMPARATOR
Intervention: CXA-101 (single doses of 250, 500, 1,000, 1,500, and 2,000 mg)
Number of subjects: 64
Study 20457817 — intervention group
Group type: COMPARATOR
Intervention: CXA-101 (multiple doses of 500 mg every 8 h, 1,000 mg every 8 h, and 1,500 mg every 12 h for 10 days)
Number of subjects: 64
Study 20457817 — intervention group
Group type: EXPERIMENTAL
Intervention: CXA-101 (1-hour infusion)
Number of subjects: 64
Study 17920365 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 509
Study 17920365 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 509
Study 15932167 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-reflux surgery (open or laparoscopic fundoplication)
Number of subjects: 373
Study 15932167 — intervention group
Group type: COMPARATOR
Intervention: Medical care (non-operated controls)
Number of subjects: 373
Study 12456849 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine (50 or 100 mg daily for 28 days)
Number of subjects: 398
Study 12456849 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (1 mg per kilogram every other day for a total of 15 injections)
Number of subjects: 398
Study 10350032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline (3 mg/kg per day, mean dose 2.2 mg/kg per day)
Number of subjects: 35
Study 10350032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7668935 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrofocusing technique for serum alkaline phosphatase isoenzymes
Number of subjects: 135
Study 2401750 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxzide (25 mg of hydrochlorothiazide and 37.5 mg of triamterene)
Number of subjects: 30
Study 2401750 — intervention group
Group type: COMPARATOR
Intervention: Dyazide (25 mg of hydrochlorothiazide and 50 mg of triamterene)
Number of subjects: 30
Study 2401750 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxzide
Number of subjects: 30
Study 2401750 — intervention group
Group type: COMPARATOR
Intervention: Dyazide
Number of subjects: 30
Study 453712 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy followed by respiratory therapy for 48 hours
Number of subjects: 31
Study 453712 — intervention group
Group type: COMPARATOR
Intervention: Respiratory therapy alone for 48 hours
Number of subjects: 31
Study 453712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 31922429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ads with the phrase 'tobacco and water'
Number of subjects: 1577
Study 31922429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ads with all tactics together
Number of subjects: 1577
Study 31922429 — intervention group
Group type: COMPARATOR
Intervention: Eco-friendly language and plant imagery
Number of subjects: 1577
Study 31922429 — intervention group
Group type: COMPARATOR
Intervention: Control condition (none of the tactics)
Number of subjects: 1577
Study 31789006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled hemostasis (systolic blood pressure + 20 mmHg)
Number of subjects: 86
Study 31789006 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostasis (15 mL air injection)
Number of subjects: 86
Study 31789006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study 30910149 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA), 1 capsule/day starting from the 21st day of the cycle prior to gonadotropin stimulation.
Number of subjects: 232
Study 30910149 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 capsule/day starting from the 21st day of the cycle prior to gonadotropin stimulation.
Number of subjects: 232
Study 30910149 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 232
Study 30910149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 28609257 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care (PC) intervention
Number of subjects: 178
Study 28609257 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 178
Study 26724241 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Infant Massage-Parenting Enhancement Program (IMPEP)
Number of subjects: 138
Study 26724241 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Enhancement Program (PEP)
Number of subjects: 138
Study 26724241 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care parenting resources)
Number of subjects: 138
Study 23702621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin or clindamycin before skin incision
Number of subjects: 896
Study 23702621 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin or clindamycin after cord clamp
Number of subjects: 896
Study 21334262 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol (75 mL four times a day for 4 days)
Number of subjects: 265
Study 21334262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sugar solution equivalent volume)
Number of subjects: 265
Study 21334262 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 265
Study 21334262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 19374148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) examination of the tongue base
Number of subjects: 41
Study 19374148 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography
Number of subjects: 41
Study 19374148 — intervention group
Group type: COMPARATOR
Intervention: Physical examination
Number of subjects: 41
Study 16886163 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose lopinavir-ritonavir
Number of subjects: 0
Study 16886163 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 15237694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (5 mg/kg)
Number of subjects: 30
Study 15237694 — intervention group
Group type: COMPARATOR
Intervention: Matched intravenous placebo
Number of subjects: 30
Study 11157690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 19768
Study 9024728 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz stent implantation
Number of subjects: 533
Study 9024728 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 533
Study 8123409 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1
Number of subjects: 43